Orexigen (OREX) Reports In-Line Q2 Loss; Plans European MAA for Contrave
Tweet Send to a Friend
Orexigen Therapeutics, Inc. (NASDAQ: OREX) reported Q2 EPS of ($0.19), in-line with the analyst estimate of ($0.19).
Orexigen also ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Orexigen also ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
